A Preliminary Evaluation of the Physiological Mechanisms of Action for Sleep Restriction Therapy
Table 4
Means (M) and standard deviations (SD) of polysomnographic data.
Sleep variables
Evaluation periods
Baseline (BN2) M (SD)
Treatment
Posttreatment M (SD)
Follow-up M (SD)
1st nights (TR3, TR4) M (SD)
Sleep stabilized M (SD)
Treatment responders ( = 3, except at follow-up = 2)
SOL (min)
51.8 (69.9)
13.0 (15.5)
7.7 (7.6)
14.8 (11.1)
46.0 (65.0)
WASO (min)
55.1 (25.9)
26.2 (14.3)
17.5 (17.5)
42.0 (56.9)
32.5 (29.9)
TST (min)
330.1 (80.5)
306.7 (32.6)
348.5 (18.6)
350.9 (37.3)
371.5 (29.4)
SE (%)
74.8 (16.3)
88.2 (4.4)
92.5 (4.6)
86.3 (11.6)
85.2 (14.5)
% stage 2
52.1 (6.4)
49.9 (6.9)
46.5 (4.9)
55.3 (6.8)
54.7 (8.1)
% stages 3-4
21.9 (5.1)
23.7 (7.5)
24.6 (3.9)
14.0 (19.8)
15.6 (8.1)
% REM
17.8 (5.0)
22.7 (5.5)
25.2 (2.8)
27.5 (4.2)
26.1 (2.4)
Nonresponders ( = 2 for baseline and 1st nights, then, = 1)
SOL (min)
17.1 (13.0)
18.0 (7.7)
6.3 (6.7)
5.3 (0.4)
28.0 (24.5)
WASO (min)
115.5 (73.6)
26.3 (8.5)
64.3 (27.9)
55.8 (2.5)
64.8 (15.2)
TST (min)
302.4 (85.1)
289.1 (39.2)
285.0 (25.5)
312.8 (1.1)
385.8 (40.7)
SE (%)
68.8 (14.9)
86 (3.5)
79.5 (6.4)
83.0 (0.0)
80.0 (8.5)
% stage 2
56.0 (5.3)
54.8 (8.7)
70.1 (1.6)
56.0 (4.9)
63.0 (1.8)
% stages 3-4
15.8 (4.4)
18.7 (10.2)
2.0 (1.7)
10.5 (3.6)
6.2 (5.1)
% REM
21.9 (8.0)
21.2 (5.3)
24.9 (0.3)
32.2 (2.0)
27.7 (6.9)
BN2: baseline night 2; TR3: the third night in lab and the first of treatment; TR4: the fourth night in lab and the second of treatment; SOL: sleep-onset latency; WASO: wake time after sleep-onset; TST: total sleep time; SE: sleep efficiency; REM: rapid eye movement; min: minutes.